National Vision (EYE)
(Delayed Data from NSDQ)
$16.01 USD
0.00 (0.00%)
Updated May 16, 2024 04:00 PM ET
After-Market: $16.00 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.01 USD
0.00 (0.00%)
Updated May 16, 2024 04:00 PM ET
After-Market: $16.00 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Zacks News
National Vision (EYE) Rides on Robust Growth Across All Lines
by Zacks Equity Research
National Vision (EYE) continues to register strong segmental performances.
Teleflex Hits New 52-Week High: What's Driving the Rally?
by Zacks Equity Research
Teleflex (TFX) is optimistic about maintaining growth momentum on several recent developments.
Thermo Fisher Rides on New Product Suite, Currency Woes Stay
by Zacks Equity Research
Thermo Fisher Scientific (TMO) recently unveils a product suite comprising the TSQ Altis, Quantis MD mass spectrometers and Vanquish MD HPLC.
Masimo's Neonatal RD SET Pulse Oximetry Sensors Get FDA Nod
by Zacks Equity Research
Masimo (MASI) will cater to the whole prenatal patient population, with the recent FDA clearance within the SET pulse oximetry business.
Hologic (HOLX) Divests Cynosure to Focus on Women's Health
by Zacks Equity Research
Hologic (HOLX) expects to witness favorable outcomes from the sell-off of the Cynosure medical aesthetics business, which was its loss-making arm since 2017.
Here's Why You Should Add NuVasive Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about NuVasive (NUVA) on its stellar segmental performance in Q3.
Edwards (EW) Rides on Innovation Despite Regulatory Issues
by Zacks Equity Research
Edwards Lifesciences' (EW) HemoSphere all-in-one monitoring platform is gaining momentum on the back of a strong rollout that sees a full-market launch.
Product Launches Aid Intersect ENT (XENT) Despite Cost Woes
by Zacks Equity Research
Intersect ENT (XENT) recently closes its ENCORE study, a small 50-patient open label program designed to evaluate the safety of the repetitive use of SINUVA.
Bruker (BRKR) Rides High on Strong Nano Sales, New Buyouts
by Zacks Equity Research
Bruker (BRKR) is reaping solid synergy benefits from the acquisitions of Anasys, JPK and Alicona.
Neogen (NEOG) Q2 Earnings & Revenues Miss, Margin Rises
by Zacks Equity Research
Neogen Corporation (NEOG) disappoints investors with dismal second-quarter fiscal 2020 results. However, the Food Safety segment showcased a robust performance.
GNC Holdings Launches Energy Drink With Natural Extracts
by Zacks Equity Research
GNC Holdings (GNC) launches natural ingredient-based energy drink MAD PONY ENERGY.
NuVasive (NUVA) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Neogen's (NEOG) Soleris for EBAC Receives AOAC's Clearance
by Zacks Equity Research
Neogen's (NEOG) Soleris test gets clearance from the AOAC, paving the way for efficient prevention of food contamination.
EYE vs. AHCO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EYE vs. AHCO: Which Stock Is the Better Value Option?
Zimmer Biomet Focuses on Priority Areas Despite Pricing Woes
by Zacks Equity Research
Zimmer Biomet (ZBH) is executing well within its priority areas like quality remediation, supply recovery efforts and product rollouts.
Medtronic's (MDT) Brain Therapies Device Receives FDA Approval
by Zacks Equity Research
Medtronic (MDT) strengthens its robotics platform with the receipt of regulatory approval and the subsequent upgradation of its enabling technology portfolio.
Medtronic Acquires Klue to Strengthen Diabetes Management Arm
by Zacks Equity Research
Medtronic (MDT) strengthens its diabetes business through the Klue acquisition and subsequent development of its PCL technology.
Globus Medical Rides on New Product Menu, U.S. Spine Business
by Zacks Equity Research
Globus Medical's (GMED) U.S. Spine business is securing a market share on the back of competitive representative recruiting and an implant pull-through from ExcelsiusGPS installations.
Boston Scientific Hits New 52-Week High: What's Driving it?
by Zacks Equity Research
Boston Scientific (BSX) is optimistic about sustaining the growth momentum on recent positive developments.
Boston Scientific's First Single-Use Duodenoscope Gets FDA Nod
by Zacks Equity Research
Boston Scientific's (BSX) EXALT Model D single-use duodenoscope gets clearance from the FDA for use in ERCP procedures.
Bruker Launches Luxendo TruLive3D Imager, Expands NANO Arm (Revised)
by Zacks Equity Research
Bruker's (BRKR) latest Luxendo TruLive3D Imager revolutionizes cell culture live imaging in natural environments.
CVS Health Rides on Aetna Prospects, Strong Selling Season
by Zacks Equity Research
CVS Health's (CVS) 2020 PBM selling season is approaching closure and the 2021 selling season is ongoing.
Omnicell-Huron Sign a Pact for Outcome-Based Expert Services
by Zacks Equity Research
Omnicell (OMCL) partners Huron to provide customers with committed expertise.
Bruker Launches Luxendo TruLive3D Imager in Mass Spectrometry
by Zacks Equity Research
Bruker's (BRKR) Luxendo TruLive3D Imager revolutionizes cell culture live imaging in natural environment.
Globus Medical Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Globus Medical (GMED) is optimistic about sustaining its growth momentum on recent positive developments.